EUVIMEDEUVIMED entdecken
Crossref

Heterozygous Prothrombin Mutation-Associated Thrombophilia

Xi Wu, Lei Li, Zhengjing Lu, Xiaobo Hu, Yeling Lu, Yu Liu, Guanqun Xu, Qiulan Ding, Xuefeng Wang, Wenman Wu, Peipei Jin, Jing Dai

Thrombosis and Haemostasis · 01.01.2025 · 125 (01) · 069-081

DOI: 10.1055/a-2350-8338 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.01.2025. Verfasst von Xi Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Prothrombin, Thrombophilia, Heterozygote, Mutation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: General Program of National Natural Science Foundation of China, Shanghai Excellent Young Talent Training Program in Public Health, Shanghai Pujiang Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Venous thromboembolism (VTE) is predisposed by thrombotic mutations in patients with hereditary thrombophilia. Although prothrombin deficiencies caused by homozygous or compound heterozygous mutations are associated with bleeding diathesis, rare cases have shown a correlation between heterozygous prothrombin mutations and thrombosis. Materials and Methods We surveyed genetic variants involved in thrombosis and hemostasis in 347 patients with unprovoked VTE or having a positive family history of thrombosis. For patients identified with heterozygous prothrombin mutations, we conducted family investigations and performed a thrombin generation test (TGT) to elucidate the thrombotic risk. Novel mutants were expressed and subjected to functional assays to clarify the underlying thrombotic mechanisms.

Results

Heterozygous prothrombin mutations were identified in 3.5% of patients (12/347), including three novel mutations Phe382Ser, Phe382Leu, and Asp597Tyr found in one patient each, as well as previously reported Arg541Trp mutation in four patients and Arg596Gln mutation in five patients. A total of 42 mutation carriers were identified within the 12 pedigrees, among whom 64.3% (27/42) had experienced thrombotic events. TGT results demonstrated hypercoagulability for carriers of the five mutations, with Arg596Gln showing the highest thrombin generation potential followed by Arg541Trp. The Phe382-associated mutations severely impaired thrombomodulin-binding ability of thrombin, resulting in obviously reduced protein C (PC) activation. The Asp597Tyr mutation exhibited a mild reduction in both inactivation by antithrombin and PC activation reactions.

Conclusion

The presence of heterozygous prothrombin mutations represents a potential genetic predisposition for VTE. All thrombosis-associated mutations potentiate coagulation activity by either conferring antithrombin resistance and/or impairing PC pathway activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProthrombinThrombophiliaHeterozygoteMutationGenetic Predisposition to DiseasePedigreeThrombinHumansFemaleMaleAdultMiddle AgedAgedVenous ThromboembolismAdolescentYoung AdultBlood Coagulation TestsBlood CoagulationProtein CAged, 80 and overRisk FactorsDNA Mutational AnalysisChild

Substanzen

ProthrombinThrombinProtein C

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Shanghai Center for Clinical Laboratory, Shanghai, China.
  • Department of Laboratory Medicine, College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Collaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Förderung

  • General Program of National Natural Science Foundation of China
  • Shanghai Excellent Young Talent Training Program in Public Health
  • Shanghai Pujiang Program

Zitieren

APA

Wu, X., Li, L., Lu, Z., Hu, X., Lu, Y., Liu, Y., Xu, G., Ding, Q., Wang, X., Wu, W., Jin, P., & Dai, J. (2025). Heterozygous Prothrombin Mutation-Associated Thrombophilia. Thrombosis and Haemostasis, 125(01), 069-081. https://doi.org/10.1055/a-2350-8338

Vancouver

Wu X, Li L, Lu Z, Hu X, Lu Y, Liu Y, et al. Heterozygous Prothrombin Mutation-Associated Thrombophilia. Thrombosis and Haemostasis. 2025;125(01):069-081. doi:10.1055/a-2350-8338

BibTeX
@article{Wu2025,
  author = {Wu, Xi and Li, Lei and Lu, Zhengjing and Hu, Xiaobo and Lu, Yeling and Liu, Yu and Xu, Guanqun and Ding, Qiulan and Wang, Xuefeng and Wu, Wenman and Jin, Peipei and Dai, Jing},
  title = {Heterozygous Prothrombin Mutation-Associated Thrombophilia},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {01},
  pages = {069--081},
  doi = {10.1055/a-2350-8338}
}
Kostenlos starten →